Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca’s Business Development Head Grady Outlines Strategy Mix

Executive Summary

AstraZeneca’s total focus on its core therapy areas will ensure it keeps building external collaborations and doing deals to generate new therapies while maximizing revenues, but outright sales of non-core mature medicines are likely to be fewer going forward, according to the company’s head of business development.

You may also be interested in...



2016 Pharma Dealmaking: Waiting On The High-Value Deals

Six pharma deals announced thus far in 2016 carried up-front values of $1 billion or more, down considerably from the high-volume, high-value M&A industry experienced the prior two years. Pharma manufacturers appear to be recalibrating – digesting previous acquisitions, adjusting to new biotech valuations and taking stock of the political and macro-economic climate – but fundamentals suggest pharma dealmaking will pick up. Pfizer’s $14 billion offer for Medivation might represent a turning point.

AstraZeneca Sells Small-Molecule Antibiotics To Pfizer But Still Investing In R&D

AstraZeneca is selling its late-stage small molecule antibiotics business to Pfizer in a deal that could reach more than $1.5bn, but the company – one of just a few big pharmas working in antibiotics R&D – says it will continue to study novel antibiotics via its MedImmune biologics division.

UK Pharma's 'Brexit Playbook' Might Envision New Regulator Roles

Britain's life sciences sector is compiling detailed game plan for September talks with the new Conservative government to promote its interests once the UK leaves the EU. All options are being considered – including possible establishment of a best-in-class regulatory agency in Britain.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1128165

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel